Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

For patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), the efficacy and safety of novel P2Y12 antagonists, including prasugrel or ticagrelor, has...

Source: BMC Cardiovascular Disorders - March 12, 2020 Category: Cardiology Authors: Zhe Wang, Da-Yan Zhou, Yong Su, Liang-Yi Si and Qiang Xu Tags: Research article Source Type: research